- Home
- MYGN
MYGN
Myriad Genetics Inc.
as of 02-27-2026 3:53pm EST
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 399.9M | IPO Year: | 1996 |
| Target Price: | $8.06 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Hold | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.95 | EPS Growth: | -180.14 |
| 52 Week Low/High: | $3.76 - $11.44 | Next Earning Date: | 05-15-2026 |
| Revenue: | $771,400,000 | Revenue Growth: | 2.33% |
| Revenue Growth (this year): | 7.26% | Revenue Growth (next year): | 5.09% |
| P/E Ratio: | -1.23 | Index: | N/A |
| Free Cash Flow: | -43500000.0 | FCF Growth: | N/A |
AI-Powered MYGN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Myriad Genetics Inc. (MYGN)
Director
Avg Cost/Share
$4.66
Shares
48,000
Total Value
$223,728.00
Owned After
281,951
SEC Form 4
Director
Avg Cost/Share
$4.80
Shares
50,407
Total Value
$242,104.82
Owned After
281,951
SEC Form 4
Director
Avg Cost/Share
$4.74
Shares
6,100
Total Value
$28,889.60
Owned After
281,951
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Phanstiel S. Louise | MYGN | Director | Feb 27, 2026 | Buy | $4.66 | 48,000 | $223,728.00 | 281,951 | |
| Phanstiel S. Louise | MYGN | Director | Feb 26, 2026 | Buy | $4.80 | 50,407 | $242,104.82 | 281,951 | |
| Phanstiel S. Louise | MYGN | Director | Feb 25, 2026 | Buy | $4.74 | 6,100 | $28,889.60 | 281,951 |
Compare MYGN vs Leading Stocks
See how MYGN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MYGN Myriad Genetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.